OPTIMIZING CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED NK CELL-MEDIATED CYTOTOXICITY COMBINED WITH ANTI-CD 20 OR ANTI-CD79 THERAPEUTIC ANTIBODIES AND NKTR-255 IN BURKITT LYMPHOMA (BL). (October 2022) - Chu, Y.; Tian, M.; Marcondes, M.; Overwijk, W.; Lee, D.; Klein, C.; Cairo, M.